Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Urology
Published in: BMC Urology 1/2020

Open Access 01-12-2020 | Nephrectomy | Research article

Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis

Authors: Yuan Shao, Bo Wu, Wei Jia, Zikuan Zhang, Qian Chen, Dongwen Wang

Published in: BMC Urology | Issue 1/2020

Login to get access

Abstract

Background

Numerous studies show that the pretreatment neutrophil-to-lymphocyte ratio (NLR) is associated with the prognosis of patients with RCC. However, their findings are inconsistent, urging us to explore the prognostic value of NLR in RCC patients.

Methods

This study was pre-registered in PROSPERO (CRD42020167131). Two reviewers independently performed a systematical search of PubMed, Web of Science, EMBASE, and Cochrane Library databases for prospective or retrospective cohort studies investigating the prognostic value of pretreatment NLR. Hazard ratios with 95% confidence intervals for overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), cancer-specific survival (CSS), and other useful clinicopathological features were extracted and analyzed with fixed or random-effect models by using Review Manager 5.3 and Stata 12.0 software. Heterogeneity was estimated on the basis of Cochran’s Q test and I2 value. Sensitivity analyses and subgroup analyses were also performed to explore the potential sources of heterogeneity. Publication bias was assessed with funnel plots and precisely assessed by Egger’s tests. The quality of the evidence was evaluated in accordance with the Grading of Recommendations Assessment, Development, and Evaluation (GRADE).

Results

Overall, 6461 RCC patients from 24 retrospective studies and 1 prospective study were included. In overall population, elevated pretreatment NLR was associated with poorer OS (pooled HR = 1.90, 95% CI = 1.56–2.30, p < 0.001; I2 = 87%), DFS/PFS (pooled HR = 2.09, 95% CI: 1.49–2.94, p < 0.001; I2 = 99%), and CSS (pooled HR = 2.31, 95% CI: 1.61–3.33, p < 0.001; I2 = 14%). Furthermore, this negative association was further confirmed in patients with nonmetastatic and metastatic RCC patients, respectively. We also investigated the predictive role of NLR in metastatic RCC patients treated with immune checkpoint inhibitors (ICIs). The results indicated that the level of NLR was significantly associated with OS (pooled HR = 3.92, 95% CI: 2.00–7.69, p < 0.001; I2 = 0%) and PFS (pooled HR = 2.20, 95% CI: 95% CI: 1.61–3.01, p < 0.001; I2 = 20%).

Conclusions

This study demonstrated that elevated pretreatment NLR was significantly associated with poor prognosis of RCC patients. NLR could be helpful as a potential prognostic biomarker to guide clinical decision-making and select individualized treatment strategies for RCC patients.
Appendix
Available only for authorised users
Literature
1.
2.
Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, Gore JL, Sun M, Wood C, Russo P. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75(1):74–84.PubMedCrossRef
3.
Moch H, Cubilla A, Humphrey P, Reuter V, Ulbright T. The 2016 WHO classification of Tumours of the urinary system and male genital organs-part a: renal, penile, and testicular Tumours. Eur Urol. 2016;70(1):93–105.PubMedCrossRef
4.
5.
Khandia R, Munjal A. Interplay between inflammation and cancer. Adv Protein Chem Struct Biol. 2020;119:199–245.PubMedCrossRef
6.
McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12(3):223–6.PubMedCrossRef
7.
Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, Kosteva JA, Ciunci CA, Gabriel PE, Thompson JC. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer. 2017;7(1):13–20.
8.
Wu Y, Li C, Zhao J, Yang L, Liu F, Zheng H, Wang Z, Xu Y. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis. World J Surg Oncol. 2016;14(1):289–93.PubMedPubMedCentralCrossRef
9.
Cho HB, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, Lee K. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother. 2009;58(1):15–23.PubMedCrossRef
10.
Dalpiaz O, Luef T, Seles M, Stotz M, Stojakovic T, Rummer K, Zigeuner R, Hutterer GC, Pichler M. Critical evaluation of the potential prognostic value of the pretreatment-derived neutrophil-lymphocyte ratio under consideration of C-reactive protein levels in clear cell renal cell carcinoma. Br J Cancer. 2017;116(1):85–90.PubMedCrossRef
11.
Shirotake S, Takamatsu K, Mizuno R, Kaneko GO, Nishimoto K, Oya M, Oyama M. Serum lactate dehydrogenase before Nivolumab treatment could be a therapeutic prognostic biomarker for patients with metastatic clear cell renal cell carcinoma. Anticancer Res. 2019;39(8):4371–7.PubMedCrossRef
12.
Nunno VD, Mollica V, Gatto L, Santoni M, Cosmai L, Porta C, Massari F. Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. Immunotherapy. 2019;11(7):631–43.PubMedCrossRef
13.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.PubMedCrossRef
14.
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8(1):16.PubMedPubMedCentralCrossRef
15.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34.PubMedCrossRef
16.
17.
Guyatt G, Oxman A, Akl E, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–94.PubMedCrossRef
18.
Chen Z, Wang K, Lu H, Xue D, Fan M, Zhuang Q, Yin S, He X, Xu R. Systemic inflammation response index predicts prognosis in patients with clear cell renal cell carcinoma: a propensity score-matched analysis. Cancer Manag Res. 2019;11:909–19.PubMedPubMedCentralCrossRef
19.
Huszno J, Kolosza Z, Mrochem-Kwarciak J, Rutkowski T, Skladowski K. The role of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and platelets in the prognosis of metastatic renal cell carcinoma. Oncology. 2019;97(1):7–17.PubMedCrossRef
20.
Ishihara H, Tachibana H, Takagi T, Kondo T, Fukuda H, Yoshida K, Iizuka J, Kobayashi H, Okumi M, Ishida H, et al. Predictive impact of peripheral blood markers and C-reactive protein in Nivolumab therapy for metastatic renal cell carcinoma. Target Oncol. 2019;14(4):453–63.CrossRefPubMed
21.
Silagy A, Flynn J, Mano R, Blum K, Marcon J, DiNatale R, Sanchez A, Carlo M, Motzer R, Coleman J, et al. Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma. Urol Oncol. 2019;37(11):9–16.CrossRef
22.
Suzuki K, Terakawa T, Furukawa J, Harada K, Hinata N, Nakano Y, Fujisawa M. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab. Int J Clin Oncol. 2019;25(1):135–44.PubMedCrossRef
23.
Takagi T, Fukuda H, Kondo T, Ishihara H, Yoshida K, Kobayashi H, Iizuka J, Okumi M, Ishida H, Tanabe K. Prognostic markers for refined stratification of IMDC intermediate-risk metastatic clear cell renal cell carcinoma treated with first-line tyrosine kinase inhibitor therapy. Target Oncol. 2019;14(2):179–86.PubMedCrossRef
24.
Tu X, Wang F, Chang T, Zhang C, Zhang M, Liu Z, Qiu S, Yang L, Wei Q. Predictive value of preoperative neutrophil-to-lymphocyte ratio in non-metastatic papillary renal cell carcinoma patients after receiving curative surgery. Cancer Manag Res. 2019;11:7515–24.PubMedPubMedCentralCrossRef
25.
Widz D, Mitura P, Buraczynski P, Plaza P, Bar M, Cabanek M, Nowak G, Ostrowska A, Bar K. Preoperative neutrophil-lymphocyte ratio as a predictor of overall survival in patients with localized renal cell carcinoma. Urol J. 2020;17(1):30–5.PubMed
26.
Zheng Y, Bao LM, Ye J, Pan Y, Wang Q, Gao X. Impact of diabetes mellitus on the prognostic value of the neutrophil-lymphocyte ratio in renal cell carcinoma. Exp Ther Med. 2019;17(2):1268–75.PubMed
27.
Kim SH, Kwon WA, Kim S, Joung JY, Seo HK, Lee KH, Chung J. The neutrophil-to-lymphocyte ratio makes the Heng risk model improve better the prediction of overall survival in metastatic renal cell cancer patients. Jpn J Clin Oncol. 2018;48(9):835–40.PubMedCrossRef
28.
Zahoor H, Barata PC, Jia X, Martin A, Allman KD, Wood LS, Gilligan TD, Grivas P, Ornstein MC, Garcia JA, et al. Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab. J Immunother Cancer. 2018;6(1):107.PubMedPubMedCentralCrossRef
29.
Zheng Y, Bao L, Wang W, Wang Q, Pan Y, Gao X. Prognostic impact of the controlling nutritional status score following curative nephrectomy for patients with renal cell carcinoma. Medicine. 2018;97(49):e13409.PubMedPubMedCentralCrossRef
30.
Chang X, Zhang F, Liu T, Wang W, Guo H. Neutrophil-to-lymphocyte ratio as an independent predictor for survival in patients with localized clear cell renal cell carcinoma after radiofrequency ablation: a propensity score matching analysis. Int Urol Nephrol. 2017;49(6):967–74.PubMedCrossRef
31.
Jeyakumar G, Kim S, Bumma N, Landry C, Silski C, Suisham S, Dickow B, Heath E, Fontana J, Vaishampayan U. Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy. J Immunother Cancer. 2017;5(1):82.PubMedPubMedCentralCrossRef
32.
Grivas N, Kafarakis V, Tsimaris I, Raptis P, Hastazeris K, Stavropoulos NE. Clinico-pathological prognostic factors of renal cell carcinoma: a 15-year review from a single center in Greece. Urol Ann. 2014;6(2):116–21.PubMedPubMedCentralCrossRef
33.
Viers BR, Houston Thompson R, Boorjian SA, Lohse CM, Leibovich BC, Tollefson MK. Preoperative neutrophil-lymphocyte ratio predicts death among patients with localized clear cell renal carcinoma undergoing nephrectomy. Urol Oncol. 2014;32(8):1277–84.PubMedCrossRef
34.
Cetin B, Berk V, Kaplan MA, Afsar B, Tufan G, Ozkan M, Isikdogan A, Benekli M, Coskun U, Buyukberber S. Is the pretreatment neutrophil to lymphocyte ratio an important prognostic parameter in patients with metastatic renal cell carcinoma? Clin Genitour cancer. 2013;11(2):141–8.CrossRef
35.
de Martino M, Pantuck AJ, Hofbauer S, Waldert M, Shariat SF, Belldegrun AS, Klatte T. Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma. J Urol. 2013;190(6):1999–2004.PubMedCrossRef
36.
Fox P, Hudson M, Brown C, Lord S, Gebski V, De Souza P, Lee CK. Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. Br J Cancer. 2013;109(1):147–53.PubMedPubMedCentralCrossRef
37.
Keizman D, Gottfried M, Ish-Shalom M, Maimon N, Peer A, Neumann A, Hammers H, Eisenberger MA, Sinibaldi V, Pili R, et al. Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib. Oncologist. 2014;19(1):51–60.PubMedCrossRef
38.
Pichler M, Hutterer GC, Stoeckigt C, Chromecki TF, Stojakovic T, Golbeck S, Eberhard K, Gerger A, Mannweiler S, Pummer K, et al. Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer. 2013;108(4):901–7.PubMedPubMedCentralCrossRef
39.
Santoni M, De Giorgi U, Iacovelli R, Conti A, Burattini L, Rossi L, Luca Burgio S, Berardi R, Muzzonigro G, Cortesi E, et al. Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. Br J Cancer. 2013;109(7):1755–9.PubMedPubMedCentralCrossRef
40.
Ohno Y, Nakashima J, Ohori M, Hatano T, Tachibana M. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol. 2010;184(3):873–8.PubMedCrossRef
41.
42.
Diakos CI, Charles KA, McMillan DC, Clarke S. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–503.PubMedCrossRef
43.
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet Oncol. 2001;357(9255):539–45.CrossRef
44.
Kim TW, Lee JH, Shim KH, Choo SH, Choi JB, Ahn HS, Kim SJ, Kim SI. Prognostic significance of preoperative and follow-up neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with non-metastatic clear cell renal cell carcinoma. Invest Clin Urol. 2019;60(1):14–20.CrossRef
45.
Yamamoto Y, Matsuyama H, Matsumoto H, Sakano S, Fuji N, Oba K, Yamamoto M, Kamiryo Y, Hiragino T, Nagao K, et al. Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma. Jpn J Clin Oncol. 2020;50(2):214–20.PubMedCrossRef
46.
47.
Tsujino T, Komura K, Hashimoto T, Muraoka R, Satake N, Matsunaga T, Tsutsumi T, Yoshikawa Y, Takai T, Minami K, et al. C-reactive protein-albumin ratio as a prognostic factor in renal cell carcinoma - a data from multi-institutional study in Japan. Urol Oncol. 2019;37(11):e811–8.CrossRef
48.
Ohmura H, Uchino K, Kajitani T, Sakamoto N, Baba E. Predictive value of the modified Glasgow prognostic score for the therapeutic effects of molecular-targeted drugs on advanced renal cell carcinoma. Mol Clin Oncol. 2017;6(5):669–75.PubMedPubMedCentralCrossRef
49.
Shaul M, Fridlender Z. Tumour-associated neutrophils in patients with cancer. Nat Rev Clin Oncol. 2019;16(10):601–20.PubMedCrossRef
50.
Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):2.CrossRef
51.
Masucci MT, Minopoli M, Carriero MV. Tumor Associated Neutrophils. Their Role in Tumorigenesis, Metastasis, Prognosis and Therapy. Front Oncol. 2019;9:1146.PubMedPubMedCentralCrossRef
52.
Kusumanto YH, Dam WA, Hospers GAP, Meijer C, Mulder NH. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis. 2003;6(4):283–7.PubMedCrossRef
53.
Gooden MJM, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(1):93–103.PubMedPubMedCentralCrossRef
54.
Wang BH, Gu WJ, Wan FN, Shi GH, Ye DW. Prognostic significance of the dynamic changes of systemic inflammatory response in metastatic renal cell carcinoma. Int Braz J Urol. 2019;45(1):89–99.PubMedPubMedCentralCrossRef
55.
Boissier R, Campagna J, Branger N, Karsenty G, Lechevallier E. The prognostic value of the neutrophil-lymphocyte ratio in renal oncology: a review. Urol Oncol. 2017;35(4):135–41.PubMedCrossRef
56.
Jiang T, Qiao M, Zhao C, Li XF, Gao GH, Su CX, Ren SX, Zhou CC. Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis. Cancer Immunol Immunother. 2018;67(5):713–27.PubMedCrossRef
57.
Ohno Y, Nakashima J, Ohori M, Gondo T, Hatano T, Tachibana M. Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma. J Urol. 2012;187(2):411–7.PubMedCrossRef
58.
Ito K, Masunaga A, Tanaka N, Mizuno R, Shirotake S, Yasumizu Y, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, et al. Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma. Jpn J Clin Oncol. 2019;49(1):69–76.PubMedCrossRef
Metadata
Title
Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis
Authors
Yuan Shao
Bo Wu
Wei Jia
Zikuan Zhang
Qian Chen
Dongwen Wang
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2020
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-020-00665-8

Other articles of this Issue 1/2020

BMC Urology 1/2020 Go to the issue

Case report

PCNL in COPD patient in the sit position under local infiltration anesthesia case report

Research article

Limited utility of qPCR-based detection of tumor-specific circulating mRNAs in whole blood from clear cell renal cell carcinoma patients

Research article

The prognostic value of routine preoperative blood parameters in muscle-invasive bladder cancer

Research article

Case series of glans injuries during voluntary medical male circumcision for HIV prevention — eastern and southern Africa, 2015–2018

Case report

Small cell carcinoma of the bladder with coexisting prostate adenocarcinoma: two cases report and literature review

Research article

Cerebral oxygenation in 45-degree trendelenburg position for robot-assisted radical prostatectomy: a single-center, open, controlled pilot study